ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
Our goal is to change treatment paradigms in orphan and rare disease—specifically targeting the chronic inflammatory pathway while avoiding immuno-suppression. TAVNEOS, our first commercial drug product, and each of our drug candidates are designed to selectively block a specific chemoattractant receptor.
We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
Company Details
- Employees
- 49
- Founded
- -
- Address
- 835 Industrial Road,
- Phone
- 16502102910
- in****@****ryx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- chemocentryx.com
- Keywords
- Biopharmaceutical, autoimmune diseases, inflammatory disorders, orphan and rare diseases, ANCA-associated vasculitis, oral therapeutics, immuno-oncology, Hidradenitis Suppurativa, Chronic Kidney Disease, Diabetic Nephropathy, Pancreatic Cancer, C3 Glomerulopathy, Small Molecule Therapeutics, Chemoattractant System, Chemokine, Drug Discovery, Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis (RA), Avacopan, Complement Receptor, ADVOCATE, AURORA, LUMINA, TAVNEOS.
- HQ
- San Carlos, California
Chemocentryx Questions
Chemocentryx's helpline number is 16502102910
Chemocentryx's website is chemocentryx.com
Chemocentryx's LinkedIn profile is https://www.linkedin.com/company/chemocentryx
Chemocentryx has
49 employees.
View email and phone details for 49
employees at Chemocentryx.
Chemocentryx's industry is
Biotechnology Research
Chemocentryx's top competitors are
Allergan,
Abbvie,
Sanofi,
Horizon,
Roche,
Novartis,
Amgen,
Astrazeneca,
Onyx Pharmaceuticals, Inc., An Amgen Subsidiary,
Pfizer.
Chemocentryx's support email address is info@chemocentryx.com
Chemocentryx's categories are Biotechnology Research
Chemocentryx's founding year is 1997
